Novavax to Participate in BofA Securities 2024 Health Care Conference

Rhea-AI Summary

Novavax (Nasdaq: NVAX) announced its participation in the BofA Securities 2024 Health Care Conference. The event will feature a fireside chat on May 15, 2024, from 3:00 to 3:30 p.m. PDT at the Encore Hotel in Las Vegas, moderated by Alec Stranahan, PhD. John C. Jacobs, President and CEO of Novavax, will represent the company. The session aims to discuss Novavax's progress with its protein-based vaccines and Matrix-M™ adjuvant. A recording of the session will be available for 30 days on the company's website.

Positive

• Novavax's participation in the high-profile BofA Securities 2024 Health Care Conference boosts its visibility among investors.
• Presence of CEO John C. Jacobs signals strong leadership and confidence in the company's direction.
• The event provides a platform to discuss recent advancements in protein-based vaccines and the Matrix-M™ adjuvant.

Negative

• No new product launches or pivotal clinical trial results announced, which may be seen as a lack of immediate growth drivers.
• If the information shared during the event does not meet investor expectations, it could negatively affect the stock price.
• Replaying the event for only 30 days limits the long-term availability of information for late investors.

GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

Conference Details:
Fireside Chat
Date:		Wednesday, May 15, 2024
Time:		3:00 – 3:30 p.m. Pacific Daylight Time (PDT)
Location:		Encore Hotel in Las Vegas, NV
Moderator:		Alec Stranahan, PhD, Equity Research – U.S. Biopharma
Novavax participant:		John C. Jacobs, President and Chief Executive Officer
Conference
Event:		Investor Meetings
Date:		Wednesday, May 15, 2024

Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2024-health-care-conference-302143793.html

SOURCE Novavax, Inc.

FAQ

When is Novavax participating in the BofA Securities 2024 Health Care Conference?

Novavax is participating on May 15, 2024.

What time is the Novavax fireside chat at the BofA Securities 2024 Health Care Conference?

The fireside chat is scheduled from 3:00 to 3:30 p.m. Pacific Daylight Time.

Where is the BofA Securities 2024 Health Care Conference held?

The conference is held at the Encore Hotel in Las Vegas, NV.

Who will represent Novavax at the BofA Securities 2024 Health Care Conference?

John C. Jacobs, President and CEO of Novavax, will represent the company.

How long will the recording of the Novavax session be available?

The recording will be available for 30 days on the company's website.

What topics will be discussed by Novavax at the BofA Securities 2024 Health Care Conference?

Novavax will discuss its progress in protein-based vaccines and the Matrix-M™ adjuvant.